Movement Alert｜Sanofi Falls 3.02% in Pre-Market Trading, Aftershocks From Core Pipeline Drug Phase III Trial Failure Continue

Market Focus06-22

On June 22, Sanofi fell 3.02% in pre-market trading, trading at $41.1/share, with turnover of approximately $299,300. The stock continues to face selling pressure following the company's announcement on June 10 that it terminated the Phase III MOBILIZE study of its core pipeline drug riliprubart for refractory chronic inflammatory demyelinating polyneuropathy (CIDP).

An independent data monitoring committee's interim analysis concluded that the study was unlikely to meet its pre-specified efficacy endpoints, prompting the termination. Riliprubart had been viewed as a critical pipeline asset for Sanofi, and the failure disrupts the company's strategy of relying on new product launches to sustain growth momentum. With blockbuster drug Dupixent facing patent cliff pressure, persistent uncertainty surrounding the R&D pipeline continues to weigh on the stock. The decline follows a 3.11% drop on June 18 as the market digests the negative pipeline development.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1172001342?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-22 18:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1172001342","market":"us","top_or_hot":-1,"title":"Movement Alert｜Sanofi Falls 3.02% in Pre-Market Trading, Aftershocks From Core Pipeline Drug Phase III Trial Failure Continue","media":"Market Focus","content":"<p><p>On June 22, Sanofi fell 3.02% in pre-market trading, trading at $41.1/share, with turnover of approximately $299,300. The stock continues to face selling pressure following the company's announcement on June 10 that it terminated the Phase III MOBILIZE study of its core pipeline drug riliprubart for refractory chronic inflammatory demyelinating polyneuropathy (CIDP).</p><p>An independent data monitoring committee's interim analysis concluded that the study was unlikely to meet its pre-specified efficacy endpoints, prompting the termination. Riliprubart had been viewed as a critical pipeline asset for Sanofi, and the failure disrupts the company's strategy of relying on new product launches to sustain growth momentum. With blockbuster drug Dupixent facing patent cliff pressure, persistent uncertainty surrounding the R&D pipeline continues to weigh on the stock. The decline follows a 3.11% drop on June 18 as the market digests the negative pipeline development.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Sanofi Falls 3.02% in Pre-Market Trading, Aftershocks From Core Pipeline Drug Phase III Trial Failure Continue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Sanofi Falls 3.02% in Pre-Market Trading, Aftershocks From Core Pipeline Drug Phase III Trial Failure Continue\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-22 18:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 22, Sanofi fell 3.02% in pre-market trading, trading at $41.1/share, with turnover of approximately $299,300. The stock continues to face selling pressure following the company's announcement on June 10 that it terminated the Phase III MOBILIZE study of its core pipeline drug riliprubart for refractory chronic inflammatory demyelinating polyneuropathy (CIDP).</p><p>An independent data monitoring committee's interim analysis concluded that the study was unlikely to meet its pre-specified efficacy endpoints, prompting the termination. Riliprubart had been viewed as a critical pipeline asset for Sanofi, and the failure disrupts the company's strategy of relying on new product launches to sustain growth momentum. With blockbuster drug Dupixent facing patent cliff pressure, persistent uncertainty surrounding the R&D pipeline continues to weigh on the stock. The decline follows a 3.11% drop on June 18 as the market digests the negative pipeline development.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNY","symbol_name":"赛诺菲安万特","start_time":0,"source_url":"","article_id":"1172001342","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1172001342","pubTimestamp":1782123624,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 22, Sanofi fell 3.02% in pre-market trading, trading at $41.1/share, with turnover of approximately $299,300. The stock continues to face selling pressure following the company's announcement...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SNY":"赛诺菲安万特"},"translate_title":"动静快讯|赛诺菲盘前跌3.02%核心管线药物三期试验失败余震不断","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNY":1},"content_text":"On June 22, Sanofi fell 3.02% in pre-market trading, trading at $41.1/share, with turnover of approximately $299,300. The stock continues to face selling pressure following the company's announcement on June 10 that it terminated the Phase III MOBILIZE study of its core pipeline drug riliprubart for refractory chronic inflammatory demyelinating polyneuropathy (CIDP).An independent data monitoring committee's interim analysis concluded that the study was unlikely to meet its pre-specified efficacy endpoints, prompting the termination. Riliprubart had been viewed as a critical pipeline asset for Sanofi, and the failure disrupts the company's strategy of relying on new product launches to sustain growth momentum. With blockbuster drug Dupixent facing patent cliff pressure, persistent uncertainty surrounding the R&D pipeline continues to weigh on the stock. The decline follows a 3.11% drop on June 18 as the market digests the negative pipeline development.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1172001342","isCrawlerRequest":true}